Antibodies against human cd38
AssigneeGenmab A/S
InventorsMichel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
Life of this patent
Estimating the term…
Abstract
Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Claims15
1-74. (canceled)
An isolated nucleic acid encoding an antibody that binds to human CD38 (SEQ ID NO:
- 52), wherein the antibody does not bind to a variant of human CD38, wherein Asp in position 202 has been substituted with Gly, to the same degree that it binds to human CD38.
A method for detecting the presence of CD38 antigen, or a cell expressing CD38, in a sample comprising:
- contacting the sample with an anti-CD38 antibody, wherein the antibody does not bind to a variant of human CD38 wherein Asp in position 202 has been substituted with Gly to the same degree that it binds to human CD38, under conditions that allow for formation of a complex between the antibody and CD38;
- and
- analyzing whether a complex has been formed.
A method of inhibiting growth and/or proliferation, or migration, or inducing phagocytosis of a cell expressing CD38, comprising contacting the cell with an antibody that binds to human CD38 (SEQ ID NO:
- 52), wherein the antibody does not bind to a variant of human CD38 wherein Asp in position 202 has been substituted with Gly to the same degree that it binds to human CD38, an immunoconjugate comprising the antibody, or a bispecific antibody comprising the antibody, such that the growth and/or proliferation, or migration of the cell is inhibited, or phagocytosis of the cell is induced.
A method of treating a disease or disorder involving cells expressing CD38 comprising administering to a subject in need thereof an antibody that binds to human CD38 (SEQ ID NO:
- 52), wherein the antibody does not bind to a variant of human CD38 wherein Asp in position 202 has been substituted with Gly to the same degree that it binds to human CD38, an immunoconjugate comprising the antibody, or a bispecific antibody comprising the antibody.
Dependencies are inferred from the claim text.